More Yaz problems for Bayer. The FDA warned Bayer regarding quality control issues at a plant that makes the key ingredient in Yaz, a birth control drug that has generated 50 different lawsuits for issues unrelated to its manufacturing process.
The FDA said inspectors uncovered testing problems at Bayer’s manufacturing plant in Bergkamen, Germany, during a March visit. FDA inspectors said the company measured the quality of its drug ingredients based on an average of several samples, instead of reporting individual test results. Bayer shipped eight drug batches to the U.S. that were tested using this randomized method, which is not permissible under FDA regulations. The FDA’s message is simple: test them all.
Along with the over-promotion of Yaz, this is one more issue that – while arguably not relevant at trial in a DVT case – underscores the disaster that is Yaz/Yasmin.
Our Yaz lawyers are now investigating for potential lawsuits and, hopefully, future settlements of Yaz, Ocella, and Yasmin claims, primarily for deep vein thrombosis and victims but also for others who have suffered gallbladder injuries, a heart attack or stroke while taking Yaz or Yasmin.
Yaz Class Action Lawsuit
Yaz is a birth control pill that was first approved by the U.S. Food and Drug Administration (FDA) in 2006. It was marketed as a combination hormonal contraceptive that also treated symptoms of premenstrual dysphoric disorder (PMDD) and acne. However, soon after its release, reports of serious side effects began to surface, leading to a large number of lawsuits. In order to efficiently manage these lawsuits, the U.S. Judicial Panel on Multidistrict Litigation (JPML) centralized a large number of these cases into a Multi-District Litigation (MDL).
MDLs are a type of mass tort lawsuit that are used to consolidate similar cases into one federal court. The purpose of creating an MDL is to streamline the pre-trial process and reduce duplicative efforts and costs. In the case of the Yaz class action lawsuit, all federal suits were consolidated in the Southern District of Illinois before Judge David R. Herndon in 2009.
Yaz lawsuits were filed by women who claimed that they suffered serious side effects from taking Yaz, including deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and heart attack. These women alleged that Bayer failed to adequately warn consumers about the potential risks associated with taking the drug, and that the company marketed Yaz as a safer alternative to other birth control pills despite having knowledge of its potential dangers.
Bayer faced thousands of lawsuits from women who claimed they suffered from serious side effects as a result of taking Yaz. The most common side effects included blood clots, heart attacks, strokes, gallbladder disease, and death. The lawsuits were filed by women who claimed that they suffered from these side effects after taking Yaz. Some of these women were extremely young and suffered injuries they still carry with them to this day from taking Yaz.
In order to resolve these lawsuits, Bayer agreed to settle the majority of the claims in the Yaz class action lawsuit. The settlements were structured as both individual and class action settlements. The individual settlements were made to women who suffered serious side effects as a result of taking Yaz. The class action settlements were made to women who took Yaz but did not suffer serious side effects.
The settlements were designed to compensate women for the harm they suffered as a result of taking Yaz. The compensation was designed to cover medical expenses, lost wages, and other expenses related to their injuries. In some cases, the settlements also provided compensation for pain and suffering and other non-economic damages.
The Yaz MDL cost Bayer billions and spawned many lessons that Bayer did not learn as evidence by the Roundup litigation. The settlements provided compensation to women who suffered serious side effects as a result of taking Yaz, and helped to hold Bayer accountable for its failure to warn victims.
Our firm is not handling these claims in 2023.